New combo vaccine shows promise in halting aggressive lung cancer
NCT ID NCT04487756
First seen Jun 03, 2026 · Last updated Jun 09, 2026 · Updated 3 times
Summary
This study tested a maintenance treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer. After standard chemotherapy and an immunotherapy drug, patients received a personalized vaccine made from their own immune cells, plus continued immunotherapy. The goal was to see if this combination could delay cancer progression and improve survival. The trial involved 20 participants across three hospitals in Spain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clínic Barcelona
Barcelona, Barcelona, 08036, Spain
-
ICO Badalona
Badalona, Barcelona, 08916, Spain
-
Quirón Dexeus
Barcelona, Barcelona, 08028, Spain
Conditions
Explore the condition pages connected to this study.